女性絕經(jīng)后由于雌激素水平降低，極易發(fā)生骨質(zhì)疏松，而臨床上常用的抗骨質(zhì)疏松藥不良反應(yīng)明顯，因此將新藥研發(fā)的重點(diǎn)轉(zhuǎn)向天然來源的植物雌激素。植物雌激素化學(xué)結(jié)構(gòu)與17β-雌二醇相似，主要包括異黃酮類、木脂素類、香豆素類化合物，具有多種生理活性；其在體內(nèi)可與雌激素受體結(jié)合并產(chǎn)生雙向調(diào)節(jié)作用，即在不同情況下表現(xiàn)出雌激素樣或抗雌激素作用。植物雌激素可通過多種作用機(jī)制防治絕經(jīng)后骨質(zhì)疏松，實(shí)驗(yàn)研究和臨床研究均表明當(dāng)歸、杜仲等中藥含有的植物雌激素類物質(zhì)，諸如染料木黃酮、大豆異黃酮及補(bǔ)骨脂對(duì)絕經(jīng)后骨質(zhì)疏松療效確切，具有開發(fā)利用前景。

Women after menopause due to sex hormones decrease are prone to osteoporosis. However, clinical anti-osteoporosis drugs are imperfect and with some adverse effects. Accordingly, the focus on new drug study was shifted to estrogenic alternative medicine- natural phytoestrogens which includes isoflavones, lignans and coumarins and were found to have a variety of physiological activities with similar chemical structure to 17β-estradiol. Phytoestrogens combined with estrogen receptor have a bidirection regulation in vivo, that is, to show estrogenic or anti-estrogen effect in different conditions and play an important role in prevention and treatment of postmenopausal osteoporosis by multiple mechanisms. Experimental and clinical studies have proved that phytoestrogenic substances， such as genistein, soy isoflavones, and psoralea from angelica, eucommia, and other phytomedicine, have the exact effects on postmenopausal osteoporosis with the considerable development prospect.

天津市中醫(yī)藥管理局課題（11025）